Has Paul Sorajja, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,092,366 in general payments to Paul Sorajja, MD across 1,109 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Paul Sorajja, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Paul Sorajja, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Paul Sorajja, MD

Interventional Cardiology · Phoenix, AZNPI 1205809308

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $754,670 of the $1,092,366 with a category attached, or 69.1%. Abbott accounts for 62.2% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2023 at $221,044 and has fallen 76.1% since, to $52,918 in 2025. Among interventional cardiology clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,092,366in general payments, 2019–2025

Across 1,109 payments — averaging $985.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Abbott$679K
W. L. Gore & Associates, Inc.$125K
Admedus Corporation$101K
Medtronic$75K
Boston Scientific$71K
Edwards Lifesciences$16K
plus $26K from 20 others

$7,696,910in research payments, 2019–2025

Across 994 payments — averaging $7743.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Abbott$5.7M
Medtronic$1000K
Edwards Lifesciences$766K
Boston Scientific$240K
Bayer$9K

What the payments were for

Consulting fees$754,67069%
Speaking & faculty fees$187,96017%
Grants$950%
Travel & lodging$110,95910%
Food & beverage$38,6584%
Education$240%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Abbott	661	$679,151
W. L. Gore & Associates, Inc.	61	$125,380
Admedus Corporation	2	$101,000
Medtronic(2 entities)	165	$75,043
Boston Scientific	99	$70,692
Edwards Lifesciences	69	$15,503
GE HealthCare	10	$6,462
Opsens Inc.	2	$3,350
Philips North America LLC	3	$3,038
Teleflex LLC	5	$3,022
Cardiva Medical, Inc.	4	$2,837
Baylis Medical Company Inc	1	$2,338
Livanova USA, Inc.	2	$1,508
Siemens Medical Solutions USA, Inc.	7	$1,114
Biosense Webster, Inc.	2	$877
Shockwave Medical, Inc	1	$750
Croivalve Inc	3	$62
B. Braun Interventional Systems Inc.	2	$47
Penumbra, Inc.	1	$39
Angiodynamics, Inc.	2	$38
Abiomed	1	$28
Atricure, Inc.	1	$27
Chiesi USA, Inc.	2	$24
Heartflow, Inc.	1	$16
Stryker	1	$16
Cardiovascular Systems Inc.	1	$3

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,092,366 in reported general payments places this provider in the 95th percentile of 223 interventional cardiology providers in Arizona.

See all interventional cardiology providers in Arizona →

Medicare billing

Part B allowed, 2024

$268,129

Medicare patients

420

Services billed

848

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
JardianceEmpagliflozin	26	$35,850
EliquisApixaban	31	$30,474
Torsemide	46	$554
Metoprolol Succinate	19	$490
Atorvastatin Calcium	16	$306
Amlodipine Besylate	23	$250
Lisinopril	27	$250
Losartan Potassium	14	$234
Rosuvastatin Calcium	14	$225
Carvedilol	19	$193
Hydrochlorothiazide	18	$179
Amoxicillin	14	$19

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Phoenix

Timothy ByrnePhoenix$614K
Haidar YassinPhoenix$434K
Akil LoliPhoenix$160K
Nishant GuptaPhoenix$145K
Richard HeuserPhoenix$68K
Nezar FallujiPhoenix$50K
Ahmad JabriPhoenix$39K
Edward EvansPhoenix$36K
Basil Al KhatibPhoenix$33K
Sourabh AggarwalPhoenix$29K

See the full list for Arizona →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →